The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Rational Design of Small Molecule Inhibitors Targeting RhoA Subfamily Rho GTPases
Open accessAbstract
SUMMARY Rho GTPases have been implicated in diverse cellular functions and are potential therapeutic targets. By virtual screening, we have identified a Rho specific inhibitor, Rhosin. Rhosin contains two-aromatic rings tethered by a linker, and it binds to the surface area sandwiching Trp58 of RhoA with a submicromolar Kd and effectively inhibits GEF-catalyzed RhoA activation. In cells Rhosin specifically inhibited RhoA activity and RhoA-mediated cellular function without affecting Cdc42 or Rac1 signaling activities. By suppressing RhoA or RhoC activity Rhosin could inhibit mammary sphere formation by breast cancer cells, suppress invasion of mammary epithelial cells, and induce neurite outgrowth of PC12 cells in synergy with NGF. Thus, the rational designed RhoA subfamily specific small molecule inhibitor is useful for studying the physiological and pathologic roles of Rho GTPase.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305
The Guanine Nucleotide-Binding Switch in Three Dimensions
Vetter, I. R., & Wittinghofer, A. (2001) · Science · doi:10.1126/science.1062023 · Cited by 1,875
GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors
Rossman, K. L., Der, C. J., & Sondek, J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1587 · Cited by 1,697
Rational design and characterization of a Rac GTPase-specific small molecule inhibitor
Gao, Y., Dickerson, J. B., Guo, F., Zheng, J., & Zheng, Y. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307512101 · Cited by 1,091 · cited 5×
“…previously we have successfully identified a chemical compound, NSC23766, that specifically binds to the surface groove of Rac1 required for interaction with GEFs and effectively inhibits Rac1 activity in diverse physiological and pathological systems (Gao et al., 2004; Akbar et al., 2006).”
InfluentialSelf-citationCrystal structure of Rac1 in complex with the guanine nucleotide exchange region of Tiam1
Worthylake, D. K., Rossman, K. L., & Sondek, J. (2000) · Nature · doi:10.1038/35047014 · Cited by 355
Rho family proteins and Ras transformation: the RHOad less traveled gets congested
Zohn, I. M., Campbell, S. L., Khosravi-Far, R., Rossman, K. L., & Der, C. J. (1998) · Oncogene · doi:10.1038/sj.onc.1202181 · Cited by 352
Deciphering the transcriptional complex critical for RhoA gene expression and cancer metastasis
Chan, C.-H., Lee, S.-W., Li, C.-F., Wang, J., Yang, W.-L., Wu, C.-Y., Wu, J., Nakayama, K. I., Kang, H.-Y., Huang, H.-Y., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2047 · Cited by 209 · cited 2×
“Both RhoA and its closely related subfamily member, RhoC, have been implicated in promoting breast cancer cell migration, invasion and metastasis (Pille et al., 2005; Chan et al., 2010; Brantely-Sieders et al., 2008).”
Characterization of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases
(2008) · Methods in Enzymology · doi:10.1016/s0076-6879(07)00409-0 · Cited by 126 · cited 1×
“…M anuscript (Sebti, et al., 2003)), Rho GTPases themselves (e.g. by bacteria toxins (Genth et al., 2008) or small molecules (Gao et al., 2004; Onesto et al., 2008)) and downstream effectors (e.g. ROCK and SRF (Narumiya et al., 2000; Evelyn et al., 2010), of the GTPase signaling pathways, but…”
Cited by
Lampi, M. C., & Reinhart-King, C. A. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao0475 · Cited by 551
Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma
Kakiuchi, M., Nishizawa, T., Ueda, H., Gotoh, K., Tanaka, A., Hayashi, A., Yamamoto, S., Tatsuno, K., Katoh, H., Watanabe, Y., et al. (2014) · Nature Genetics · doi:10.1038/ng.2984 · Cited by 505
Cook, D. R., Rossman, K. L., & Der, C. J. (2014) · Oncogene · doi:10.1038/onc.2013.362 · Cited by 378
Rho GTPase signaling in cancer progression and dissemination
Crosas-Molist, E., Samain, R., Kohlhammer, L., Orgaz, J. L., George, S. L., Maiques, O., Barcelo, J., & Sanz-Moreno, V. (2022) · Physiological Reviews · doi:10.1152/physrev.00045.2020 · Cited by 272
Kctd13 deletion reduces synaptic transmission via increased RhoA
Escamilla, C. O., Filonova, I., Walker, A. K., Xuan, Z. X., Holehonnur, R., Espinosa, F., Liu, S., Thyme, S. B., López-García, I. A., Mendoza, D. B., et al. (2017) · Nature · doi:10.1038/nature24470 · Cited by 165
A small molecule inhibitor of Rheb selectively targets mTORC1 signaling
Mahoney, S. J., Narayan, S., Molz, L., Berstler, L. A., Kang, S. A., Vlasuk, G. P., & Saiah, E. (2018) · Nature Communications · doi:10.1038/s41467-018-03035-z · Cited by 88
Bonney, S., Seitz, S., Ryan, C. A., Jones, K. L., Clarke, P., Tyler, K. L., & Siegenthaler, J. A. (2019) · mBio · doi:10.1128/mbio.01675-19 · Cited by 79
Francis, T. C., Gaynor, A., Chandra, R., Fox, M. E., & Lobo, M. K. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.02.007 · Cited by 61
“Here, we utilized a novel, small molecule Rho-GTPase inhibitor Rhosin, which selectively targets RhoA (21).”
Ephrin‐ A 1‐ EphA4 signaling negatively regulates myelination in the central nervous system
Harboe, M., Torvund‐Jensen, J., Kjaer‐Sorensen, K., & Laursen, L. S. (2018) · Glia · doi:10.1002/glia.23293 · Cited by 56
“To substantiate that RhoA activation is required for the inhibition of process extension following EphA4 stimulation, oligodendrocyte precursors were plated on PDL or ephrin-A1 in the absence or presence of a specific RhoA inhibitor, Rhosin (Shang et al., 2012) (Figure 4g).”
Pharmacological Modulators of Small GTPases of Rho Family in Neurodegenerative Diseases
Guiler, W., Koehler, A., Boykin, C., & Lu, Q. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.661612 · Cited by 51
Profibrotic epithelial phenotype: a central role for MRTF and TAZ
Bialik, J. F., Ding, M., Speight, P., Dan, Q., Miranda, M. Z., Di Ciano-Oliveira, C., Kofler, M. M., Rotstein, O. D., Pedersen, S. F., Szászi, K., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-40764-7 · Cited by 41
Targeting Small GTPases and Their Prenylation in Diabetes Mellitus
Gendaszewska-Darmach, E., Garstka, M. A., & Błażewska, K. M. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00410 · Cited by 35
RHO Family GTPases in the Biology of Lymphoma
Voena, C., & Chiarle, R. (2019) · Cells · doi:10.3390/cells8070646 · Cited by 35
Zhang, Y., Larraufie, M.-H., Musavi, L., Akkiraju, H., Brown, L. M., & Stockwell, B. R. (2018) · Biochemistry · doi:10.1021/acs.biochem.7b01113 · Cited by 16
Therapeutic Targeting the Allosteric Cysteinome of RAS and Kinase Families
Li, L., Meyer, C., Zhou, Z.-W., Elmezayen, A., & Westover, K. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167626 · Cited by 14
Metadata
- Authors
- Shang, X., Marchioni, F., Sipes, N., Evelyn, C. R., Jerabek-Willemsen, M., Duhr, S., Seibel, W., Wortman, M., & Zheng, Y.
- Venue
- Chemistry & Biology
- Publisher
- Elsevier BV
- Published
- 2012-06
- Volume
- 19
- Issue
- 6
- Pages
- 699-710
- ISSN
- 1074-5521 (ISSN-L)
- OpenAlex
- W1969882218
- Cited by
- 224
- References
- 8
- FWCI
- 3.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.